DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zanosar (Streptozocin) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

WARNING

ZANOSAR should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.

A patient need not be hospitalized but should have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and to protect and maintain a patient compromised by drug toxicity. Renal toxicity is dose-related and cumulative and may be severe or fatal. Other major toxicities are nausea and vomiting which may be severe and at times treatment-limiting. In addition, liver dysfunction, diarrhea, and hematological changes have been observed in some patients. Streptozocin is mutagenic. When administered parenterally, it has been found to be tumorigenic or carcinogenic in some rodents.

The physician must judge the possible benefit to the patient against the known toxic effects of this drug in considering the advisability of therapy with ZANOSAR. The physician should be familiar with the following text before making a judgment and beginning treatment.

 

ZANOSAR SUMMARY

ZANOSAR® (streptozocin sterile powder)

Each vial of ZANOSAR contains 1 g of the active ingredient streptozocin 2-deoxy-2 [[(methylnitrosoamino)carbonyl]amino]-α (and ß)-D-glucopyranose and 220 mg citric acid anhydrous. ZANOSAR is available as a sterile, pale yellow, freeze-dried preparation for intravenous administration. The pH was adjusted with sodium hydroxide. When reconstituted as directed, the pH of the solution will be between 3.5 and 4.5.

ZANOSAR is indicated in the treatment of metastatic islet cell carcinoma of the pancreas. Responses have been obtained with both functional and nonfunctional carcinomas. Because of its inherent renal toxicity, therapy with this drug should be limited to patients with symptomatic or progressive metastatic disease.


See all Zanosar indications & dosage >>

ZANOSAR NEWS HIGHLIGHTS

Media Articles Related to Zanosar (Streptozocin)

Radiation Before Surgery Improves Pancreatic Cancer Outcomes
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2008.11.26]

ASGE And The Pancreatic Cancer Action Network Partner To Raise Awareness About Pancreatic Cancer
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2008.11.25]

GenVec Announces Interim Survival Data In Pivotal Trial Of TNFerade™ In Locally Advanced Pancreatic Cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2008.11.20]

Radiosurgery Proves Viable for Some Pancreatic Cancers
Source: MedicineNet Pancreatic Cancer Specialty [2008.09.23]

Pancreatic Cancer
Source: MedicineNet Pancreatic Cancer Specialty [2008.08.15]

more >>

Published Studies Related to Zanosar (Streptozocin)

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. [2005.08.01]

Taurine rescues vascular endothelial dysfunction in streptozocin-induced diabetic rats: Correlated with downregulation of LOX-1 and ICAM-1 expression on aortas. [2008.11.12]

The antidiabetic effects of cysteinyl metformin, a newly synthesized agent, in alloxan- and streptozocin-induced diabetic rats. [2008.05.09]

Cardioprotective effects of grape seed proanthocyanidins extracts in streptozocin induced diabetic rats. [2007.11]

Oral route of mini-proinsulin-expressing Ganoderma lucidum decreases blood glucose level in streptozocin-induced diabetic rats. [2007.07]

more >>

Clinical Trials Related to Zanosar (Streptozocin)

Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors [Recruiting]

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors [Recruiting]

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms [Active, not recruiting]

Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas [Completed]

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract. [Recruiting]

more >>

Page last updated: 2008-11-26

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008